Heron Therapeutics Inc. (NASDAQ:HRTX) shares traded down 2.2% during trading on Thursday . The company traded as low as $18.86 and last traded at $19.01, with a volume of 270,451 shares changing hands. The stock had previously closed at $19.43.

A number of research analysts have commented on the stock. Cowen and Company reissued a “buy” rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Jefferies Group reissued a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, April 28th. Cantor Fitzgerald reissued a “buy” rating on shares of Heron Therapeutics in a research report on Sunday, May 8th. Noble Financial reissued a “buy” rating and set a $51.00 target price on shares of Heron Therapeutics in a research report on Wednesday, April 20th. Finally, Brean Capital reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Monday, April 18th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $50.30.

The company has a 50 day moving average price of $17.53 and a 200-day moving average price of $18.90.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.92). Analysts anticipate that Heron Therapeutics Inc. will post ($3.65) EPS for the current year.

A number of hedge funds and institutional investors recently bought and sold shares of the stock. Bank of Montreal Can bought a new position in Heron Therapeutics during the fourth quarter worth approximately $3,010,000. California Public Employees Retirement System boosted its stake in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 81,200 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares in the last quarter. Russell Frank Co boosted its stake in shares of Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock valued at $1,369,000 after buying an additional 15,585 shares in the last quarter. Finally, GAM Holding AG boosted its stake in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock valued at $1,119,000 after buying an additional 9,400 shares in the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.